The Treatment of Hairy Cell Leukemia

Video

Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, comments on the treatment of patients with hairy cell leukemia.

Clinical Pearls

Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, comments on the treatment of patients with hairy cell leukemia.

  • Patients with hairy cell leukemia typically receive cladribine or pentostatin and experience a long remission
  • Patients are able to respond again to cladribine or pentostatin following relapse
  • There are limited options for those who have gone through many lines of therapy
Recent Videos
Related Content
FGFR-Altered NMIBC Treatment Advances With TAR-210 Findings

FGFR-Altered NMIBC Treatment Advances With TAR-210 Findings

Jordyn Sava
November 21st 2024
Article

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

FDA Updates Fludarabine Labeling Under Project Renewal Initiative

FDA Updates Fludarabine Labeling Under Project Renewal Initiative

Jordyn Sava
November 20th 2024
Article

The FDA updated the fludarabine phosphate injection labeling under Project Renewal, clarifying the dosage for combination therapy and streamlining safety warnings.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

FDA Approves Revumenib in KMT2A-Rearranged Acute Leukemia

FDA Approves Revumenib in KMT2A-Rearranged Acute Leukemia

Jordyn Sava
November 15th 2024
Article

Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia.

Read More

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Jonah Feldman
November 15th 2024
Article

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

Read More